The latest on Methuselah, health span research, and regenerative medicine
Despite the vast population Alzheimer’s disease affects each year, no new drugs have been approved by the FDA in 16 years. The lack of success in AD drug development has infused scepticism in the field. This recent scientific publication shows the latest developments in the AD drug pipeline as of 2019.
Read MoreHere is a fun question... Can you name one hole in your body that, if sewn shut, would help you function better?
Assuming you have an anatomically normal body, the answer is none. While saying that "bad plumbing" causes Alzheimer's Disease is an oversimplification, it is a great way to quickly explain why we angel invested in Leucadia Therapeutics in 2015. The Principal Scientist, Founder, and CEO of Leucadia Therapeutics, Doug Ethell, Ph.D., had an Occam Razor's approach to AD, which was refreshing to us and an inspiration. As it turns out, the Cribriform Plate that drains cerebrospinal fluid can get ossified or clogged as you age. In AD patients, it is always significantly clogged, thus the "bad plumbing" analogy.
At Methuselah Foundation we understand that the war against AD is one that humanity cannot afford to loose. We applaud revisiting the roadmap that will lead us to a cure. Writer John Carroll analyses this imperative in the Endpoints News article titled "After yet another PhIII Alzheimer’s failure, experts try to map a path out of the wrecking field."
Read MoreIn light of the underwhelming efficacy of human anti-Abeta clinical trials in the last several years, we are pleased to read the scientific community starting to reconsider the theory that amyloid beta (Abeta) is the primary causative factor in Alzheimer's disease. This paper is among several we've seen over the past year which criticizes the amyloid cascade hypothesis, and does a good job of balancing the supportive and contradictory evidence for the hypothesis.
Read More
